These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 25204374)
1. Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. Mauz-Körholz C; Hasenclever D; Holzendorf V; Bernstädt M; Jürgens H; Burdach S; Eggert A; Berthold F; Müller HL; Frühwald MC; Klingebiel T; Metzler M; Körholz D Leuk Lymphoma; 2015 May; 56(5):1308-14. PubMed ID: 25204374 [TBL] [Abstract][Full Text] [Related]
2. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479 [TBL] [Abstract][Full Text] [Related]
3. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128 [TBL] [Abstract][Full Text] [Related]
4. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026 [TBL] [Abstract][Full Text] [Related]
5. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
6. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Kelly KM; Hutchinson RJ; Sposto R; Weiner MA; Lones MA; Perkins SL; Massey V; Ann Oncol; 2002; 13 Suppl 1():107-11. PubMed ID: 12078889 [TBL] [Abstract][Full Text] [Related]
7. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014 [TBL] [Abstract][Full Text] [Related]
8. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Kelly KM; Sposto R; Hutchinson R; Massey V; McCarten K; Perkins S; Lones M; Villaluna D; Weiner M Blood; 2011 Mar; 117(9):2596-603. PubMed ID: 21079154 [TBL] [Abstract][Full Text] [Related]
9. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321 [TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. Lester EP; Petroni GR; Barcos M; Johnson JL; Millard FE; Cooper MR; Omura GA; Frei E; Peterson BA Cancer Invest; 2001; 19(5):447-58. PubMed ID: 11458812 [TBL] [Abstract][Full Text] [Related]
11. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149 [TBL] [Abstract][Full Text] [Related]
12. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440 [TBL] [Abstract][Full Text] [Related]
13. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577 [TBL] [Abstract][Full Text] [Related]
14. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Dörffel W; Lüders H; Rühl U; Albrecht M; Marciniak H; Parwaresch R; Pötter R; Schellong G; Schwarze EW; Wickmann L Klin Padiatr; 2003; 215(3):139-45. PubMed ID: 12838937 [TBL] [Abstract][Full Text] [Related]
15. ABVD or BEACOPP Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ; Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705 [TBL] [Abstract][Full Text] [Related]
16. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751 [TBL] [Abstract][Full Text] [Related]
17. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592 [TBL] [Abstract][Full Text] [Related]
18. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Bauer K; Skoetz N; Monsef I; Engert A; Brillant C Cochrane Database Syst Rev; 2011 Aug; (8):CD007941. PubMed ID: 21833963 [TBL] [Abstract][Full Text] [Related]
19. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220 [TBL] [Abstract][Full Text] [Related]
20. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. Ozuah NW; Marcus KJ; LaCasce AS; Billett AL J Pediatr Hematol Oncol; 2018 Aug; 40(6):e338-e342. PubMed ID: 29293187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]